The LSM10 antibody is designed to target the LSM10 protein, a member of the Like-Sm (LSM) family involved in RNA metabolism. LSM proteins are conserved across eukaryotes and typically form complexes that bind small nuclear RNAs (snRNAs) or small nucleolar RNAs (snoRNAs), playing roles in RNA processing, splicing, and stability. LSM10. specifically, is part of the Sm-like protein group and associates with the U7 snRNA within the histone mRNA processing complex, critical for 3'-end maturation of replication-dependent histone mRNAs—a process essential for cell cycle progression. Unlike other LSM proteins localized in the nucleus or cytoplasm, LSM10 is predominantly found in the Cajal bodies, subnuclear structures linked to snRNP biogenesis. Research on LSM10 has focused on its role in histone gene regulation, DNA replication, and potential implications in cancers characterized by disrupted cell cycle control. Antibodies against LSM10 are utilized in techniques like immunoprecipitation, Western blotting, and immunofluorescence to study its expression, interactions, and subcellular localization. These tools have advanced understanding of RNA-protein complexes in gene expression and genome stability, offering insights into therapeutic targets for malignancies linked to histone mRNA dysregulation. Commercial LSM10 antibodies are typically validated for specificity in human or model organisms, aiding both basic and translational studies.